New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT06422520

Completed Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for signs that the tumors shrank. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGB-C354 (an antibody-drug conjugate) and tislelizumab (an immunotherapy)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early, first-in-human study with only 63 participants. The drug may not shrink tumors or could cause serious side effects. Success in this small trial does not guarantee it will work in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Dana Farber Cancer Institute

Boston, Massachusetts, 02215-5418, United States
Florida Cancer Specialist Research Institute Lake Nona

Orlando, Florida, 32827-7400, United States
Hubei Cancer Hospital

Wuhan, Hubei, 430079, China
Jilin Cancer Hospital

Changchun, Jilin, 130021, China
Liaoning Cancer Hospital and Institute

Shenyang, Liaoning, 110042, China
Next Oncology

San Antonio, Texas, 78229-6028, United States
One Clinical Research

Nedlands, Western Australia, WA 6009, Australia
St Vincents Hospital Melbourne

Fitzroy, Victoria, VIC 3065, Australia
The Alfred Hospital

Melbourne, Victoria, VIC 3004, Australia
The University of Texas Md Anderson Cancer Center

Houston, Texas, 77030-4009, United States
Washington University School of Medicine

St Louis, Missouri, 63110-1010, United States
West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China
Westmead Hospital

Westmead, New South Wales, NSW 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.